BidaskClub cut shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) from a sell rating to a strong sell rating in a report issued on Saturday morning, BidAskClub reports.

Several other analysts also recently commented on ARWR. ValuEngine raised Arrowhead Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, August 22nd. HC Wainwright reaffirmed a buy rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 24th. TheStreet downgraded Arrowhead Pharmaceuticals from a c- rating to a d+ rating in a research report on Thursday, September 3rd. Finally, Chardan Capital reaffirmed a buy rating and set a $81.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the company. The company presently has a consensus rating of Buy and a consensus price target of $62.00.

Shares of NASDAQ:ARWR opened at $33.80 on Friday. The business’s 50 day simple moving average is $40.83 and its two-hundred day simple moving average is $37.11. Arrowhead Pharmaceuticals has a 52-week low of $19.51 and a 52-week high of $73.72.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The company had revenue of $27.38 million during the quarter, compared to analysts’ expectations of $38.76 million. Arrowhead Pharmaceuticals had a negative return on equity of 5.65% and a negative net margin of 19.75%. Equities research analysts anticipate that Arrowhead Pharmaceuticals will post -0.48 earnings per share for the current year.

In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Thursday, June 25th. The stock was sold at an average price of $38.81, for a total transaction of $3,881,000.00. Following the sale, the chief executive officer now directly owns 2,605,260 shares of the company’s stock, valued at approximately $101,110,140.60. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Insiders own 4.00% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Commonwealth Equity Services LLC lifted its position in Arrowhead Pharmaceuticals by 2.6% in the 2nd quarter. Commonwealth Equity Services LLC now owns 11,968 shares of the biotechnology company’s stock valued at $516,000 after acquiring an additional 303 shares in the last quarter. Magnus Financial Group LLC raised its stake in Arrowhead Pharmaceuticals by 5.4% during the 1st quarter. Magnus Financial Group LLC now owns 8,126 shares of the biotechnology company’s stock valued at $234,000 after buying an additional 418 shares during the last quarter. Rockefeller Capital Management L.P. raised its stake in Arrowhead Pharmaceuticals by 13.3% during the 2nd quarter. Rockefeller Capital Management L.P. now owns 3,626 shares of the biotechnology company’s stock valued at $157,000 after buying an additional 426 shares during the last quarter. Hoylecohen LLC raised its stake in Arrowhead Pharmaceuticals by 2.5% during the 1st quarter. Hoylecohen LLC now owns 20,600 shares of the biotechnology company’s stock valued at $593,000 after buying an additional 500 shares during the last quarter. Finally, Creative Financial Designs Inc. ADV purchased a new stake in Arrowhead Pharmaceuticals during the 2nd quarter valued at $25,000. 66.34% of the stock is currently owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.

Recommended Story: What does an outperform rating mean?

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.